WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Google Secures Pentagon AI Deal for Classified Projects 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
BRISBANE, Calif., May 03, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced it will host a company overview webinar on Wednesday, May 10, 2017, at 1:30 p.m. ET.
Dr. Cameron Durrant, chairman and CEO, will present an update on the company, its growth initiative progress and upcoming key milestones. The webinar will feature a presentation that can be accessed via the webcast link below. A question-and-answer session will follow.
Date: Wednesday, May 10, 2017
Time: 1:30 p.m. ET (10:30 a.m. PT)
Dial-in: 1-888-267-6301
Toll/International Dial-in: 1-719-457-2734
Webcast: http://public.viavid.com/index.php?id=124313
A telephone replay will be available approximately two hours after the call through June 10, 2017. Access the replay by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 from international locations, and entering the replay pin number: 8563194.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab, for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
